Noninvasive assessment of liver steatosis using ultrasound methods

Medical Ultrasonography

Volumn 16, Issue 3, 2014, Pages 236-245

  Lupşor Platon, Monica ^a   Stefǎnescu, Horia ^a   Muresçan, Daniel ^b   Florea, Mira ^c   Erzsébet Szász, Mária ^a   Maniu, Anca ^a   Badea, Radu ^a  

^a REGIONAL INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY   (Romania)

^b Clinic of Obstetrics Gynecology   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Computerized processing; Controlled attenuation parameter; Noninvasive; Steatosis; Ultrasonography

Indexed keywords

ANALYTICAL PARAMETERS; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; HUMAN; IMAGE PROCESSING; LIPID STORAGE; LIVER BIOPSY; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; OBSERVER VARIATION; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; REPRODUCIBILITY;

FATTY LIVER; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS;

EID: 84905681765     PISSN: 18444172     EISSN: 20668643     Source Type: Journal    
DOI: 10.11152/mu.2013.2066.163.1mlp     Document Type: Review

References (69)

1. Lupsor M, Badea R. Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy? Rom J Gastroenterol 2005; 14: 419-425.
2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
3. Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: Prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52: 579- 585.
4. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
7. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
8. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
9. de Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010; 97: 1331-1339.
10. Minervini MI, Ruppert K, Fontes P, et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009; 50: 501-510.
11. Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br J Surg 2009; 96: 437-444.
12. Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004; 230: 276-280.
13. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113.
14. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004; 19: 368-374.
15. Grigorescu M, Rusu M. Non-alcoholic fatty liver disease, component of the metabolic syndrome: prevalence, profile of the risk factors. Roumanian Journal of Hepatology 2005; 1 (Suppl 1): 13-16.
16. Vilgrain V, Ronot M, Abdel-Rehim M, et al. Hepatic steatosis: a major trap in liver imaging. Diagn Interv Imaging 2013; 94: 713-727.
17. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-1582.
18. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543.
19. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044.
20. Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 481-486.
21. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
22. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445.
23. Guiu B, Loffroy R, Hillon P, Petit JM. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization! J Hepatol 2009; 51: 1082-1083.
24. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090.
25. Goldberg B, Petterson H. The Nicer Year Book 1996 Ultrasonography, The Nicer Institute, ISIS Medical Media 1996: 55-81.
26. Badea R. Ficatul. In: Badea RI, Dudea SM, Mircea PA, Stamatian F. Tratat de Ultrasonografie Clinica. Ed. Medicala, Bucuresti, 2000: 105-176.
27. Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34: 516-522.
28. Chen CL, Cheng YF, Yu CY, et al. Living donor liver transplantation: the Asian perspective. Transplantation 2014; 97 Suppl 8: S3.
29. Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging 2014 May 24. DOI 10.1007/ s13244-014-0336-2.
30. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14: 635-637.
31. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061-1067.
32. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239-244.
33. Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485- 489.
34. Wang CC, Hsieh TC, Tseng TC, et al. Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis. J Formos Med Assoc 2014; 113: 249-254.
35. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med 2009; 48: 739-746.
36. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
37. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
38. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189: 320-323.
39. Oguzkurt L, Yildirim T, Torun D, Tercan F, Kizilkilic O, Niron EA. Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol 2005; 54: 253-257.
40. Bolondi L, Li Bassi S, Gaiani S, et al. Liver cirrhosis: changes of Doppler waveform of hepatic veins. Radiology 1991; 178: 513-516.
41. Mihmanli I, Kantarci F, Yilmaz MH, et al. Effect of diffuse fatty infiltration of the liver on hepatic artery resistance index. J Clin Ultrasound 2005; 33: 95-99
42. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 2007; 61: 33-43.
43. Basaran C, Karcaaltincaba M, Akata D, et al. Fat-containing lesions of the liver: cross-sectional imaging findings with emphasis on MRI. AJR Am J Roentgenol 2005; 184: 1103-1110.
44. Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics 2005; 25: 321-331.
45. Mortele KJ, Stubbe J, Praet M, et al. Intratumoral steatosis in focal nodular hyperplasia coinciding with diffuse hepatic steatosis: CT and MRI findings with histologic correlation. Abdom Imaging 2000; 25: 179-181.
46. Khalili K, Lan FP, Hanbidge AE, Muradali D, Oreopoulos DG, Wanless IR. Hepatic subcapsular steatosis in response to intraperitoneal insulin delivery: CT findings and prevalence. AJR Am J Roentgenol 2003; 180: 1601-1604.
47. Valls C, Iannacconne R, Alba E, et al. Fat in the liver: diagnosis and characterization. Eur Radiol 2006; 16: 2292-2308.
48. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21: 1023- 1032.
49. Itai Y. Peritumoral sparing of fatty liver: another important instance of focal sparing caused by a hepatic tumor. AJR Am J Roentgenol 2000; 174: 868-870.
50. Aubin B, Denys A, Lafortune M, Dery R, Breton G. Focal sparing of liver parenchyma in steatosis: role of the gallbladder and its vessels. J Ultrasound Med 1995; 14: 77-80.
51. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
52. Taylor KJ, Gorelick FS, Rosenfield AT, Riely CA. Ultrasonography of alcoholic liver disease with histological correlation. Radiology 1981;141:157-161.
53. Meek DR, Mills PR, Gray HW, Duncan JG, Russell RI, McKillop JH. A comparison of computed tomography, ultrasound and scintigraphy in the diagnosis of alcoholic liver disease. Br J Radiol 1984; 57:23-27.
54. Yeh WC, Huang SW, Li PC. Liver fibrosis grade classification width B-mode ultrasound. Ultrasound Med Biol 2003;29:1229-1235.
55. Lin T, Ophir J, Potter G. Correlation of ultrasonic attenuation with pathologic fat and fibrosis in liver disease. Ultrasound Med Biol 1988; 14: 729-734.
56. Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Mendez-Sanchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 212-220.
57. Gaitini D, Baruch Y, Ghersin E, et al. Feasibility study of ultrasonic fatty liver biopsy: texture vs. attenuation and backscatter. Ultrasound Med Biol 2004; 30: 1321-1327.
58. Gaitini D, Lederman M, Baruch Y, et al. Computerised analysis of liver texture with correlation to needle biopsy. Ultraschall Med 2005; 26: 197-202.
59. Fujii Y, Taniguchi N, Itoh K, et al. A new method for attenuation coefficient measurement in the liver. Comparison with the spectral shift central frequency method. J Ultrasound Med 2002; 21: 783-788.
60. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996; 24: 25- 29.
61. Marshall RH, Eissa M, Bluth EI, Gulotta PM, Davis NK. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. AJR Am J Roentgenol 2012; 199: 997-1002.
62. Borges VF, Diniz AL, Cotrim HP, Rocha HL, Andrade NB. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J Clin Ultrasound 2013; 41: 18-25.
63. Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909-914.
64. Lupşor M, Badea R, Vicaş C, et al. Detection of steatosis in chronic hepatitis C, based on the evaluation of the attenuation coefficient computed on the ultrasound image. Med Ultrason 2008; 10: 13-20.
65. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835.
66. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20.
67. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253.
68. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29: 1149-1158.
69. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918.